Pressure BioSciences, Inc. · OTC:PBIO
Pressure BioSciences — SeeThruEquity NYC (November 2013)
25 slides from Pressure BioSciences's conference presentation, Nov 18, 2013
Slide 1: Investor Presentation - Pressure BioSciences, Inc.
Investor Presentation Pressure BioSciences, Inc. (OTCQB: PBIO) Discovery Starts with Sample Preparation™ Richard T. Schumacher President & CEO [email protected] SeeThruEquity NYC November 12, 2013
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain forward looking statements that reflect management’s current views and opinions as to the status of the Company’s products, technology and other future events and operations. These statements are neither a promise nor guarantee, but involve ri
Slide 3: Key Investment Highlights
Key Investment Highlights • Pressure Cycling Technology (PCT): Powerful, Enabling, Patented • Primary Application: Sample Preparation ($ Billion Market Opportunity) • PCT Products Offer Significant Advantages Over Competitive Methods • Proven Technology: ~ 235 Installations in ~150 Marquee Laborator
Slide 4: Company Background
Company Background • Formed Sept 2004 - Sale of Boston Biomedica (BBII) • Started Operations in 2006 • OTCQB: PBIO • Ten (10) Full-time Employees • Strong Management Team and Board of Directors • Focused on the Development and Commercialization of PCT-based Instruments and Consumables for the Prepar
Slide 5: Financial Data
Financial Data Historical Revenue Data • FY 2011 $ 988,000 • FY 2012 $ 1,256,000 • FY 2013 (thru Q3) $ 1,150,000 Selected Data: November 11, 2013 • Cash/AR ~$ 0.28 million • Inventory ~$ 0.87 million • Debt (other than AP) $ 450K Selected Data: September 13, 2013 • Common O/S 11.9 million • Preferre
Slide 6: Experienced Senior Management & Board
Experienced Senior Management & Board Management • Mr. Richard T. Schumacher, President & CEO Boston Biomedica (CEO, Founder); Panacos Pharma (President, Co-founder); Trinity Biotech (Founding Group); CBR Labs (Gen’l Mgr) - Harvard Medical School • Dr. Edmund Y. Ting, Senior Vice President of Engine
Slide 7: Value Proposition - Sample Prep Market
Value Proposition - Sample Prep Market • Analysis of DNA, RNA, Proteins, & Lipids (“biomolecules”) is Crucial to the Development of New Diagnostics & Therapeutics • Sample Preparation is Required Prior to Virtually All Analyses • Current Sample Preparation Methods Highly Inadequate: bottleneck • PCT
Slide 8: Release Important Biomolecules by Cell Lysis
Release Important Biomolecules by Cell Lysis 8
Slide 9: Sample Input Quality = Sample Result Quality
Sample Input Quality = Sample Result Quality Scientific research can be broken down to three key elements: sample preparation, analysis, & data reduction/interpretation “Discovery Starts with Sample Preparation” 9
Slide 10: Competitive Landscape
Competitive Landscape Mostly Commodity Products Through Catalogue Sales • Mortar & Pestle • Dounce homogenizer (glass on glass) • Potter-Elvenhjem homogenizer (Teflon on glass) • Enzymatic Digestion • Polytron shearing homogenizers • Blenders • Bead Beating • Sonication • Repeated Freeze/Thaw cycles
Slide 11: PCT Sample Preparation System
PCT Sample Preparation System Barocycler™ NEP2320 PULSE Tube MicroTubes PCT-dependent Kits 11
Slide 12: Next Gen PCT Platform: HUB Family of Barocyclers
Next Gen PCT Platform: HUB Family of Barocyclers High Pressure Generators for Multiple Research & Mfg Applications • Compact • Portable • Versatile • Computer Controlled • Labview Software Driven • Pressures to: • 20 kpsi (HUB160) 2012 • 60 kpsi (HUB440) 2012 • 100 kpsi (HUB880) Q12014 …the HUB for
Slide 13: Product Pipeline (2011 Release) The Shredder SG3
Product Pipeline (2011 Release) The Shredder SG3 Low Shear, Mechanical, Homogenization Device Long lasting lithium rechargeable batteries Paddle for convenient pressure setting Pressure force levels: 15, 30, 45 lbs. Force Uses PCT PULSE and Shredder Tubes Heavy Duty, Robust Driver Cole Parmer, a The
Slide 14: Selected Marquee Customers (40 of 150)
Selected Marquee Customers (40 of 150) • Amgen • Thermo Fisher • Biogen • Target Discovery • Lilly • Battelle Memorial Institute • Novartis • Harvard Medical School • Monsanto • Harvard School of Public Health • BM Squibb • Rockefeller University • Merck • University of New Hampshire • Centocor • Ba
Slide 15: Current Fields of Use and Applications for PCT
High Level Overview of Current Fields of Use and Applications for PCT: a Few Select Examples Proteomics (Proteins) • Biomarker Discovery: Heart Disease and Cancer • Pressure-Enhanced Enzymology: Trypsin and Deglycosylation • Enhance/Enable Protein Analysis: Mass Spectrometry, EPR, ESR, and NMR • Enh
Slide 16: PCT Focus Area: Biomarker Discovery
PCT Focus Area: Biomarker Discovery Cancer, Heart Disease, Inf. Diseases, Neurological Disorders, Etc. Dr. Andreas Huhmer - Thermo Fisher Scientific …advantages of speed and quality using PCT in mass spec workflow Dr. Michael Alterman - Tumor Vaccines and Biotechnology Branch, CBER, FDA …improved in
Slide 17: Professor Wayne Hubbell - UCLA
Professor Wayne Hubbell - UCLA Distinguished Professor of Chemistry & Biochemistry, and Jules Stein Professor at UCLA "Protein flexibility is the new frontier in understanding protein function and regulation. The study of proteins under pressure has great ability to reveal salient features of protei
Slide 18: Dr. Henry C. Lee
Dr. Henry C. Lee Professor of Forensic Science and founder of the Forensic Science Program at the University of New Haven; founder of the HC Lee Institute of Forensic Sciences; and former Commissioner of Public Safety for the State of Connecticut. “We are excited about this opportunity to collaborat
Slide 19: 2013 News of Interest
2013 News of Interest • PBI Reports Record Financial Results (revenue) for Q3 2013 Guidance Given for Strong Q4 2013 Revenue Guidance Given on Two New Instrument Systems (Q1 and Q2 2014) • PBI Announces Close of $2.0 Million Above-Market Private Placement • Core Technology Breakthrough Announced • N
Slide 20: 2013 Key Product Drivers (High Throughput PCT)
2013 Key Product Drivers (High Throughput PCT) • Breakthrough in Core PCT Technology Platform - High Throughput a) announced on June 4, 2013 b) will allow PCT sample processing with universal, high throughput multiwell format c) will allow PCT Systems to integrate with HT instruments in thousands of
Slide 21: 2013 Potential Drivers: High Throughput PCT
2013 Potential Drivers High Throughput PCT From Dream to Reality Manual Processing of Automated Processing of 24 - 96 Individual (1-48) Sample Tubes Sample Tubes (wells) Simultaneously ¥ oF | | | ee Y ~ « — 21
Slide 22: 2013 Potential Drivers: High Throughput PCT
2013 Potential Drivers: High Throughput PCT Automated liquid handling helps ensure accuracy and reproducibility, eliminates repetitive tasks, and frees personnel for other activities. 22
Slide 23: HT PCT Product Concept
2013 Potential Drivers: High Throughput PCT HT PCT Product Concept 23
Slide 24: 2013 Potential Drivers: High Throughput PCT
2013 Potential Drivers: High Throughput PCT Beta Units Ready for Testing: February 2014 Beta Site Evaluation Completed: April 2014 Commercialization: June 2014 Initial Applications • rapid protein digestion (multiple labs, worldwide) • lipid profiling (multiple diseases/disorders of the GI tract) HT
Slide 25: Slide 25
Pressure Biosciences — SeeThruEquity NYC (November 2013) on 6ix